The role of mitochondrial OXPHOS dysfunction in the development of neurologic diseases

Neurobiology of Disease

Volumn 51, Issue , 2013, Pages 27-34

  Breuer, M E ^a,b   Koopman, W J ^a   Koene, S ^b   Nooteboom, M ^a,b   Rodenburg, R J ^a,b   Willems, P H ^a   Smeitink, J A M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bioenergetics; Cellular metabolism; Mitochondrial dysfunction; Neurodegenerative diseases

Indexed keywords

ADENOSINE TRIPHOSPHATE; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BRAIN NERVE CELL; CELL MIGRATION; CELL MOTILITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; LEBER HEREDITARY OPTIC NEUROPATHY; LEIGH DISEASE; MELAS SYNDROME; MEMBRANE FUSION; MERRF SYNDROME; MITOCHONDRIAL RESPIRATION; MOLECULAR PATHOLOGY; NARP SYNDROME; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ENERGY METABOLISM; HUMANS; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; OXIDATIVE PHOSPHORYLATION;

EID: 84872675883     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.03.007     Document Type: Review

References (79)

1. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38:515-517.
2. Bennett M.C., Mlady G.W., Kwon Y.H., Rose G.M. Chronic in vivo sodium azide infusion induces selective and stable inhibition of cytochrome c oxidase. J. Neurochem. 1996, 66(6):2606-2611.
3. Bourgeron T., Rustin P., Chretien D., Birch-Machin M., Bourgeois M., Viegas-Pequignot E., Munnich A., Rotig A. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat. Genet. 1995, 11:144-149.
4. Breuer M.E., Willems P.H., Russel F.G., Koopman W.J., Smeitink J.A. Modeling mitochondrial dysfunctions in the brain: from mice to men. J. Inherit. Metab. Dis. 2011, 10.1007/s10545-011-9375-8.
5. Browne S.E., Beal M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 2006, 8:2061-2073.
6. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41(5):646-653.
7. Calabrese V., Lodi R., Tonon C., D'Agata V., Sapienza M., Scapagnini G., Mangiameli A., Pennisi G., Stella A.M., Butterfield D.A. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 2005, 233:145-162.
8. Campuzano V., Montermini L., Molto M.D., Pianese L., Cossee M., Cavalcanti F., Monros E., Rodius F., Duclos F., Monticelli A., Zara F., Canizares J., Koutnikova H., Bidichandani S.I., Gellera C., Brice A., Trouillas P., De Michele G., Filla A., De Frutos R., Palau F., Patel P.I., Di Donato S., Mandel J.L., Cocozza S., Koenig M., Pandolfo M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996, 271:1423-1427.
9. Carelli V., La Morgia C., Valentino M.L., Rizzo G., Carbonelli M., De Negri A.M., Sadun F., Carta A., Guerrioro S., Simonelli F., Sadun A.A., Aggarwal D., Liguori R., Avoni P., Baruzzi A., Zeviani M., Montagna P., Barboni P. Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011, 134(Pt. 9):e188.
10. Castillo-Quan J.I. Parkin' control: regulation of PGC-1α through PARIS in Parkinson's disease. Dis. Model. Mech. 2011, 4(4):427-429.
11. Chang D.T., Reynolds I.J. Mitochondrial trafficking and morphology in healthy and injured neurons. Prog. Neurobiol. 2006, 80(5):241-268.
12. Chen C.M. Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. Chang Gung Med. J. 2011, 34(2):135-152.
13. Chen H., Chan D.C. Emerging functions of mammalian mitochondrial fusion and fission. Hum. Mol. Genet. 2005, 14(2):R283-R289.
14. Chinnery P.F. Mitochondrial Disorders Overview. GeneReviews [Internet] 2000, University of Washington, Seattle, Seattle (WA), 1993-2000 Jun 8 [updated 2010 Sep 16]. R.A. Pagon, T.D. Bird, C.R. Dolan, K. Stephens (Eds.).
15. Chinnery P.F., Howell N., Lightowlers R.N., Turnbull D.M. Molecular pathology of MELAS and MERFF. The relationship between mutation load and clinical phenotypes. Brain 1997, 120(Pt 10):1713-1721.
16. de Castro I.P., Martins L.M., Tufi R. Mitochondrial quality control and neurological disease: an emerging connection. Expert Rev. Mol. Med. 2010, 12:1-21.
17. de Moura M.B., dos Santos L.S., Van Houten B. Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ. Mol. Mutagen. 2010, 51(5):391-405.
18. Di Filippo M., Chiasserini D., Tozzi A., Picconi B., Calbresi P. Mitochondria and the link between neuroinflammation and neurodegeneration. J. Alzheimers Dis. 2010, 20:S369-S379.
19. Dragicevic N., Mamacarz M., Zhu Y., Buzzeo R., Tan J., Arendash G.W., Bradshaw P.C. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J. Alzheimers Dis. 2010, 20(Suppl. 2):S535-S550.
20. Farrar M.A., Lin C.S., Krishnan A.V., Park S.B., Andrews P.I., Kiernan M.C. Acute, reversible axonal energy failure during stroke-like episodes in MELAS. Pediatrics 2010, 126(3):e734-e739.
21. Feng Z., Gao F. Stem cell challenges in the treatment of neurodegenerative disease. CNS Neurosci. Ther. 2011, 10.1111/j.1755-5949.2011.00239.x.
22. Filosto M., Tomelleri G., Tonin P., Scarpelli M., Vattemi G., Rizzuto N., Padovani A., Simonati A. Neuropathology of mitochondrial diseases. Biosci. Rep. 2007, 27(1-3):23-30.
23. Finsterer J. Central nervous system manifestations of mitochondrial disorders. Acta Neurol. Scand. 2006, 114(4):217-238.
24. Finsterer J. Inherited mitochondrial neuropathies. J. Neurol. Sci. 2011, 304(1-2):9-16.
25. Fornai F., Longone P., Cafaro L., Kastsiuchenka O., Ferrucci M., Manca M.L., Lazzeri G., Spalloni A., Bellio N., Lenzi P., Modungno N., Siciliano G., Isidoro C., Murri L., Ruggieri S., Paparelli A. Lithium delays progression of amyotrophic lateral sclerosis. PNAS 2008, 105(6):2052-2057.
26. Fukui H., Moraes C.T. The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis?. Trends Neurosci. 2008, 31(5):251-256.
27. Garcia-Gimenez J.L., Gimeno A., Gonzalez-Cabo P., Dasi F., Bolinches-Amoros A., Molla B., Palau F., Pallardo F.V. Differential expression of PGC-1α and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts. PLoS One 2011, 6(6):e20666.
28. Gelfand J.M., Duncan J.L., Racine C.A., Gillum L.A., Chin C.T., Zhang Y., Zhang Q., Wong L.J., Roorda A., Green A.J. Heterogeneous patterns of tissue injury in NARP syndrome. Neurol 2011, 258(3):440-448.
29. Golbidi S., Ebadi S.A., Laher I. Antioxidants in the treatment of diabetes. Curr. Diab. Rev. 2011, 7(2):106-125.
30. Goodall E.F., Morrison K.E. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev. Mol. Med. 2006, 8(11):1-22.
31. Heeman B., Van den Haute C., Aelvoet S.A., Valsecchi F., Rodenburg R.J., Reumers V., Devyser Z., Callewaert G., Koopman W.J., Willems P.H., Baekelandt V. Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J. Cell Sci. 2011, 124(Pt 7):1115-1125.
32. Hollenbeck P.J., Saxton W.M. The axonal transport of mitochondria. J. Cell Sci. 2005, 118:5411-5419.
33. Ienco E.C., LoGerfo A., Carlesi C., Orsucci D., Ricci G., Mancuso M., Siciliano G. Oxidative stress treatment for clinical trials in neurodegenerative diseases. J. Alzheimers Dis. 2011, 24(Suppl. 2):111-126.
34. Ikawa M., Okazawa H., Arakawa K., Kudo T., Kimura H., Fujibayashi Y., Kuriyama M., Yoneda M. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion 2009, 9(2):144-148.
35. Israelson A., Arbel N., Da Cruz S., Ilieva H., Yamanaka K., Shoshan-Barmatz V., Cleveland D.W. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron 2010, 67(4):575-587.
36. Jellinger K.A. Recent advances in our understanding of neurodegeneration. J. Neural Transm. 2009, 116:1111-1162.
37. Keeney P.M., Dunham L.D., Quigley C.K., Morton S.L., Bergquist K.E., Bennett J.P. Cybrid models of Parkinson's disease show variable mitochondrial biogenesis and genotype respiration relationships. Exp. Neurol. 2009, 220(2):374-382.
38. Kirkinezos I.G., Moraes C.T. Reactive oxygen species and mitochondrial diseases. Semin. Cell Dev. Biol. 2001, 12:449-457.
39. Knott A.B., Perkins G., Schwarzenbacher R., Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat. Rev. Neuro. 2008, 9:505-518.
40. Koene S., Smeitink J. Mitochondrial medicine: entering the era of treatment. J. Intern. Med. 2009, 265(2):193-209.
41. Lee H.F., Tsai C.R., Chi C.S., Lee H.J., Chen C.C. Leigh syndrome: clinical and neuroimaging follow-up. Pediatr. Neurol. 2009, 40(2):88-93.
42. Levine J.S., Cepeda C., Hickey M.A., Fleming S.M., Chesselet M.F. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci. 2004, 27(11):691-697.
43. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795.
44. MacAskill A.F., Kittler J.T. Control of mitochondrial transport and localization in neurons. Trends Cell Biol. 2009, 20(2):1-11.
45. Mancuso M., Coppede F., Migliore L., Siciliano G., Murri L. Mitochondrial dysfunction, oxidative stress and neurodegeneration. J. Alzheimers Dis. 2006, 10:59-73.
46. Masliah E., Mallory M., Hansen L., DeTeresa R., Alford M., Terry R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci. Lett. 1994, 174(1):67-72.
47. Mattiazzi M., Vijayvergiva C., Gajewski C.D., DeVivo D.C., Lenaz G., Wiedemann M., Manfredi G. The mtDNA T8993G (NARP) mutation results in an impairment of oxidative phosphorylation that can be improved by antioxidants. Hum. Mol. Genet. 2004, 13(8):869-879.
48. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60(5):748-766.
49. Mirabella M., Di Giovanni S., Silvestri G., Tonali P., Servidei S. Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. Brain 2000, 123(Pt 1):93-104.
50. Morais V.A., De Strooper B. Mitochondria dysfunction and neurodegenerative disorders: cause or consequence. J. Alzheimers Dis. 2010, 20:S255-S263.
51. Morava E., Rodenburg R.J., Hol F., de Vries M., Janssen A., van den Heuvel L., Nijtmans L., Smeitink J. Clinical and biochemical characteristics in patients with a high mutant load of the mitochondrial T8993G/C mutations. Am. J. Med. Genet. A 2006, 140(8):863-868.
52. Moreira P.I., Zhu X., Wang X., Lee H.G., Nunomura A., Petersen R.B., Perry G., Smith M.A. Mitochondria: a therapeutic target in neurodegeneration. Biochim. Biophys. Acta 2010, 1802(1):212-220.
53. Mortiboys H., Thomas K.J., Koopman W.J., Klaffke S., Abou-Sleiman P., Olpin S., Wood N.W., Willems P.H., Smeitink J.A., Cookson M.R., Bandmann O. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann. Neurol. 2008, 64(5):555-565.
54. Mounsey R.B., Teismann P. Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Park. Dis. 2010, 2011:617472.
55. Novak M.J., Tabrizi S.J. Huntington's disease. BMJ 2010, 340:c3109. 10.1136/bmj.c3109.
56. Oliveira J.M. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J. Neurochem. 2010, 114(1):1-12.
57. Pickrell A.M., Fukui H., Wang X., Pinto M., Moraes C.T. The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions. J. Neurosci. 2010, 31(27):9895-9904.
58. Rahman S., Blok R.B., Dahl H.H., Danks D.M., Kirby D.M., Chow C.W., Christodoulou J., Thorbum D.R. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann. Neurol. 1996, 39(3):343-351.
59. Reddy P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid. Redox Signal. 2008, 9(10):1647-1658.
60. Reddy P.H., Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 2008, 14:45-53.
61. Rintoul G.L., Reynolds I.J. Mitochondrial trafficking and morphology in neuronal injury. Biochim. Biophys. Acta 2010, 1802:143-150.
62. Rossignol R., Faustin B., Rocher C., Malgat M., Mazat J.P., Letellier T. Mitochondrial threshold effects. Biochem. J. 2003, 370(Pt. 3):751-762.
63. Scaglia F. The role of mitochondrial dysfunction in psychiatric disease. Dev Disabil Res Rev. 2010, 16(2):136-143.
64. Shan X., Chiang P.M., Prince D.L., Wong P.C. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc. Natl Acad. Sci. USA 2010, 107(37):16325-16330.
65. Shigemi R., Fukuda M., Suzuki Y., Morimoto T., Ishii E. L-arginine is effective in stroke-like episodes of MELAS associated with the G13513A mutation. Brain Dev. 2011, 33(6):518-520.
66. Smeitink J., van den Heuvel L., DiMauro S. The genetics and pathology of oxidative phosphorylation. Nat Gen Rev 2001, 2:342-352.
67. Smeitink J.A., Zeviani M., Turnbull D.M., Jacobs H.T. Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders. Cell Metab. 2006, 3:9-13.
68. Spelbrink J.N. Functional organization of mammalian mitochondrial DNA in nucleoids: history, recent developments, and future challenges. IUBMB Life 2010, 62(1):19-32.
69. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37(3):510-518.
70. Testai F.D., Gorelick P.B. Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Arch. Neurol. 2010, 67(1):19-24.
71. Wallace D.C., Fan W. The pathophysiology of mitochondrial disease as modeled in the mouse. Genes Dev. 2009, 23(15):1714-1736.
72. Wang Z., Qi X.K., Yao S., Chen B., Luan X., Zhang W., Han M., Yuan Y. Phenotypic patterns of MELAS/LS overlap syndrome associated with m.1351G>A mutation, and neuropathological findings in one autopsy case. Neuropathology 2010, 30(6):606-614.
73. Wang H.L., Chou A.H., Wu A.S., Chen S.Y., Weng Y.H., Kao Y.C., Yeh T.H., Chu P.J., Lu C.S. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim. Biophys. Acta 2011, 1812(6):674-684.
74. Wareski P., Vaarmann A., Choubev V., Safiulina D., Liiv J., Kuum M., Kaasik A. PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J. Biol. Chem. 2009, 284(32):21379-21385.
75. Wenz T., Williams S.L., Bacman S.R., Moraes C.T. Emerging therapeutic approaches to mitochondrial diseases. Dev. Disabil. Res. Rev. 2010, 16:219-229.
76. Wu Y.N., Johnson S.W. Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-d-aspartate currents in rat substantia nigra dopamine neurons. Neuroscience 2011, 10.1016/j.neuroscience.2011.08.041.
77. Xiong N., Huang J., Zhang Z., Zhang Z., Xiong J., Liu X., Jia M., Wang F., Chen C., Cao X., Liang Z., Sun S., Lin Z., Wang T. Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. PLoS One 2009, 4(11):e7878.
78. Xu Y.F., Gendron T.F., Zhang Y.J., Lin W.L., D'Alton S., Sheng H., Casey M.C., Tong J., Knight J., Yu X., Rademakers R., Boylan K., Hutton M., McGowan E., Dickson D.W., Lewis J., Petrucelli L. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. 2010, 30(32):10851-10859.
79. Zhou L., Chomyn A., Attardi G., Miller C.A. Myoclonic epilepsy and ragged red fibers (MERRF) syndrome: selective vulnerability of CNS neurons does not correlate with the level of mitochondrial tRNAlys mutation in individual neuronal isolates. J. Neurosci. 1997, 17(20):7746-7753.